US OptionsDetailed Quotes

KRMD241220P7500

Watchlist
  • 4.07
  • 0.000.00%
15min DelayClose Nov 27 16:00 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

Comments

    $KORU Medical Systems (KRMD.US)$
    KORU Medical Systems Presents Data at Partnership Opportunities in Drug Delivery (PODD) Conference Demonstrating Nursing Preference for Use of KORU FreedomEdge® Infusion System over Manual Syringe Administration for Subcutaneous Oncology Infusion
    KORU Medical Systems presented data at the PODD 2024 Conference showing strong nursing preference for their FreedomEdge® Infusion System over manual syringe administration for subcutaneous oncology infusions. The stud...
    $KORU Medical Systems (KRMD.US)$ Reuters · 1 min ago                                        KORU Medical Systems Receives Regulatory Clearance for Freedomedge® Infusion System in Japan
    $KORU Medical Systems (KRMD.US)$
    KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic
    KORU Medical Systems (NASDAQ: KRMD) announced a collaboration with a global pharmaceutical company to initiate a feasibility study for their Freedom Infusion System. This system, designed for subcutaneous administration, will be tested with an FDA and EMA approved oncology biologic drug currently administered manually by healthcare professionals. The Freedom System, ...
    $KORU Medical Systems (KRMD.US)$
    NEWS
    KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth
    First quarter 2024 net revenues of $8.2 million, an 11% increase YoY and record high quarterly revenues.
    Core business (U.S. and International) experienced 14% growth YoY, driven by SCIg market growth, share gains, and geographic expansion.
    Entered a Novel Therapies collaboration with an oncology drug therapy, bringing total collaborations to 16.
    G...
    $KORU Medical Systems (KRMD.US)$ KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth
    2
Read more